{"title":"Neuro-endocrine neoplasms (NENs): The necessity of a multidisciplinary approach for achieving best clinical outcomes","authors":"E. Karamitrousis, M. Liontos, N. Tsoukalas","doi":"10.2478/fco-2022-0012","DOIUrl":"https://doi.org/10.2478/fco-2022-0012","url":null,"abstract":"","PeriodicalId":38592,"journal":{"name":"Forum of Clinical Oncology","volume":"13 1","pages":"1 - 2"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48386898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
T. Rios, Ramona Souza da Silva Baqueiro Boulhosa, Maria Lúcia Varjão da Costa, Betina da Silva Sassaki, A. Bueno, R. P. de Jesus, L. P. M. de Oliveira
{"title":"Two Distinct Nutritional Assessment Tools Have Dissimilar Outcomes in a Sample of Older Adult Patients With Cancer","authors":"T. Rios, Ramona Souza da Silva Baqueiro Boulhosa, Maria Lúcia Varjão da Costa, Betina da Silva Sassaki, A. Bueno, R. P. de Jesus, L. P. M. de Oliveira","doi":"10.2478/fco-2021-0016","DOIUrl":"https://doi.org/10.2478/fco-2021-0016","url":null,"abstract":"Abstract Introduction Malnutrition is strongly associated with negative outcomes in aged populations with cancer. Several studies have compared the outcomes of nutritional-screening tools, but knowledge specifically covering older adult patients with cancer remains limited. The aim of this study was to compare the outcomes of two tools, the Patient-Generated Subjective Global Assessment (PG-SGA) versus the Mini Nutritional Assessment (MNA) for this population. Method Cross-sectional study with 432 participants who consented to participate and were enrolled at admission to medical and surgical wards of a tertiary referral hospital. The participants’ nutritional statuses were simultaneously assessed using the PG-SGA and the MNA, and the outcomes compared using the kappa statistical test. The Receiver Operating Characteristic Curve (ROC) was employed to calculate the MNA sensitivity, specificity, positive and negative predictive values, and was compared with PG-SGA. Results Prevalence of good nourishment was observed in 62.5% and 61.1% of the participants, as detected by PG-SGA and MNA, respectively. Both tools concurred moderately (kappa = 0.453). Importantly, there were significant differences in the diagnosis of malnutrition (7.6% vs. 4.6%, p = 0.000). The MNA showed sensitivity of 72.2% and specificity of 75.9% in detecting good nourishment for the population investigated. Conclusion The MNA may not present greater sensitivity, possibly due to a lack of coverage of gastrointestinal symptoms. It is a quick and efficient tool for nutritional assessment of older adult patients with cancer, but as it is more specific than sensitive, caution is recommended when identifying borderline or early malnourished individuals of this population.","PeriodicalId":38592,"journal":{"name":"Forum of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43906468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Gastrointestinal Neuroendocrine Tumours: A Single-Centre Experience","authors":"H. Yahyazadeh, M. Beheshti, S. Tahbaz","doi":"10.2478/fco-2022-0004","DOIUrl":"https://doi.org/10.2478/fco-2022-0004","url":null,"abstract":"Abstract Objectives Gastrointestinal neuroendocrine tumours (GI-NETs) are actually malignant tumours, and their most common location of metastasis is the liver. In this study, we define the epidemiologic features of NETs and investigate the demographic factors, clinicopathologic features, survival, and the oncologic results related to GI-NETs. Materials and Methods In this 10-year study (2009–2019), all GI and liver NETs were taken out from the pathology records. When classification based on the WHO classification criteria, patients were categorized based on their location, sex, age, and proliferative index. After studying clinical charts of GI-NET cases, a complete panel of IHC markers such as Chromogranin A, ‘Ki67’ and synaptophysin were used. Results: Based on published data, the liver is not a common primary site for NETs; most liver lesions are most likely to have been metastases. The mean age of patients at diagnosis was 52.72 years. In this research, 27.78% of patients had colon NETs and 27.78 liver. Two (11.11%) patients were classified as stage II, seven (38.89%) as stage III, and one (5.56%) as stage IV. After a 120-month follow-up, 13 (72.22%) patients with colorectal NETs were alive, and 5 (27.78%) of the patients had died. Conclusion Treatment of colon and rectal NETs is difficult because it affects the patient's initial site of involvement, and this often makes treatment difficult for the patient. With suitable management, the prognosis can be positive with long survival, but it is related to the tumour variation grade, the efficiency of the selected treatment, and also to the patient's adherence to the follow-up.","PeriodicalId":38592,"journal":{"name":"Forum of Clinical Oncology","volume":"0 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41697181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
O. Fiste, M. Liontos, A. Svarna, E. Gagari, F. Zagouri, M. Dimopoulos
{"title":"Paraneoplastic pemphigus associated with squamous cell carcinoma of the cervix","authors":"O. Fiste, M. Liontos, A. Svarna, E. Gagari, F. Zagouri, M. Dimopoulos","doi":"10.2478/fco-2022-0002","DOIUrl":"https://doi.org/10.2478/fco-2022-0002","url":null,"abstract":"Abstract Background Paraneoplastic pemphigus is an autoimmune skin and mucosal disorder, rarely associated with solid malignancies, with devastating impact. Patients and methods Herein, we report the case of a middle-aged patient who presented with recalcitrant stomatitis and was ultimately diagnosed with advanced-stage cervical cancer. Results Despite the prompt initiation of immunosuppressive medications, in parallel with systemic therapy for her underlying neoplasm, she eventually died within 10 months. Conclusions Considering its heterogeneous clinicopathological and immunological manifestations, paraneoplastic pemphigus remains a genuine diagnostic challenge, whereas its abysmal prognosis highlights the need of additional effective immunosuppressants.","PeriodicalId":38592,"journal":{"name":"Forum of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45443456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
D. Kartini, A. Kurnia, Shabrina Rizky Putri, Tiffany Christina Thaher, D. Handjari, L. Khoe, Kevin Varian Marcevianto
{"title":"Survival rate and prognostic factors of oral squamous cell carcinoma in Indonesia: A single-center retrospective study","authors":"D. Kartini, A. Kurnia, Shabrina Rizky Putri, Tiffany Christina Thaher, D. Handjari, L. Khoe, Kevin Varian Marcevianto","doi":"10.2478/fco-2021-0013","DOIUrl":"https://doi.org/10.2478/fco-2021-0013","url":null,"abstract":"Abstract Background Oral squamous cell carcinoma (OSCC) is the sixth most common malignancy in Asia. Most patients in Cipto Mangunkusumo Hospital have been diagnosed with an advanced stage. There had not been any survival study for OSCC in Indonesia. This study aimed to investigate the survival rate and prognostic factors of OSCC in Cipto Mangunkusumo Hospital. Methods A retrospective cohort study was conducted on OSCC patients diagnosed and treated in Cipto Mangunkusumo Hospital from 2014 to 2018. Data regarding age, gender, site of the primary lesion, clinical stage of the disease, tumor differentiation, invasion, and surgical margins were collected. The main outcomes measured were overall survival (OS) and disease-specific survival (DSS). The predictors of survival were then determined. Result 169 patients were included. The majority of patients were male (51.5%) and above 50 years old (55.6%). The most prevalent tumor site was the tongue (72.8%) followed by buccal mucosa (13%). The majority (82.2%) of patients had advanced (clinical stage IV) disease at diagnosis. A smaller majority of patients had a well-differentiated tumor (60.4%) and a low-grade tumor (53.8%). The worst one-year and two-year overall survival rates were found in the stage IV group (53.5% and 37.5%, respectively). The disease-specific survival rate was 66.9%. Conclusion The one-year and two-year overall survival rates of OSCC in Cipto Mangunkusumo Hospital were 58.6% and 43.1%. Moreover, clinical stage, tumor size, and lymph node involvement were the most significant prognostic factors for OSCC.","PeriodicalId":38592,"journal":{"name":"Forum of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44542325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Tumor Biology's struggle to survive: A tough lesson for cancer and oncology research journals","authors":"J. A. Teixeira da Silva","doi":"10.2478/fco-2022-0001","DOIUrl":"https://doi.org/10.2478/fco-2022-0001","url":null,"abstract":"Abstract Tumor Biology, owned by the International Society of Oncology and BioMarkers and currently published by IOS Press, lost its Clarivate impact factor of 3.650 in 2017. It has been plagued by over 100 retractions due to paper mills (including a batch of 15 papers published between 2014 and 2016 that were retracted at the end of 2021), faked peer reviews, and forged research. According to PubMed, the number of papers published by Tumor Biology has been reduced to a mere trickle, dropping from 707 in 2017 to 66 in 2018. It is unclear how Tumor Biology will be able to recover from such disastrous reputational damage and whether there is even merit in continuing its publication. Other journals for cancer and oncology research would do well to observe this case closely and learn from its mistakes.","PeriodicalId":38592,"journal":{"name":"Forum of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44306587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Epigenetics and cancer – A dependence relationship","authors":"E. Karamitrousis, M. Liontos, N. Tsoukalas","doi":"10.2478/fco-2022-0025","DOIUrl":"https://doi.org/10.2478/fco-2022-0025","url":null,"abstract":"","PeriodicalId":38592,"journal":{"name":"Forum of Clinical Oncology","volume":"12 1","pages":"1 - 2"},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43363256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
J. D. Moreno, G. Papageorgiou, I. Gazouli, A. Kyriazoglou
{"title":"Systemic Treatment of Ewing Sarcoma: Current Options and Future Perspectives","authors":"J. D. Moreno, G. Papageorgiou, I. Gazouli, A. Kyriazoglou","doi":"10.2478/fco-2021-0005","DOIUrl":"https://doi.org/10.2478/fco-2021-0005","url":null,"abstract":"Abstract Ewing sarcoma (ES) is an uncommon malignant neoplasm, mostly affecting young adults and adolescents. Surgical excision, irradiation, and combinations of multiple chemotherapeutic agents are currently used as a multimodal strategy for the treatment of local and oligometastatic disease. Although ES usually responds to the primary treatment, relapsed and primarily refractory disease remains a difficult therapeutic challenge. The growing understanding of cancer biology and the subsequent development of new therapeutic strategies have been put at the service of research in recurrent and refractory ES, generating a great number of ongoing studies with compounds that could find superior clinical outcomes in the years to come. This review gathers the current available information on the treatment and clinical investigation of ES and aims to be a point of support for future research.","PeriodicalId":38592,"journal":{"name":"Forum of Clinical Oncology","volume":"12 1","pages":"3 - 27"},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43649430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Immunotherapy-Induced Acute Hepatitis in the Elderly: The Case of a Patient with Urothelial Carcinoma and a Review of the Literature","authors":"Ioannou Alexandros, Papaxoinis Georgios, Dimitroulopoulos Dimitrios, Tryfonopoulos Dimitrios, Gouveris Panagiotis","doi":"10.2478/fco-2021-0003","DOIUrl":"https://doi.org/10.2478/fco-2021-0003","url":null,"abstract":"Abstract Cancer immunotherapy is an emerging beneficial treatment for cancer that acts by activating the immune system to produce antitumour effects. In particular, immune checkpoint therapy has recently provided novel strategies for cancer treatments. Nevertheless, these new therapeutic approaches have introduced immune-related adverse events to clinical practice. In the elderly, checkpoint inhibitors might have limited efficacy because of immunosenescence. Limited literature data demonstrate a higher incidence of irAEs and an earlier discontinuation of immunotherapy in these patients. We report the case of an 89-year-old male patient with metastatic urothelial carcinoma, who presented with Grade 4 immune-related hepatitis after receiving pembrolizumab treatment.","PeriodicalId":38592,"journal":{"name":"Forum of Clinical Oncology","volume":"12 1","pages":"28 - 33"},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49396835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
E. Karamitrousis, I. Balgkouranidou, N. Xenidis, K. Amarantidis, E. Biziota, T. Koukaki, S. Kakolyris
{"title":"Concentration of circulating tumour DNA in patients with metastatic gastric cancer and its prognostic significance","authors":"E. Karamitrousis, I. Balgkouranidou, N. Xenidis, K. Amarantidis, E. Biziota, T. Koukaki, S. Kakolyris","doi":"10.2478/fco-2021-0010","DOIUrl":"https://doi.org/10.2478/fco-2021-0010","url":null,"abstract":"Abstract Gastric cancer is one of the most common cancers worldwide. The amount of cell-free DNA (cfDNA) in the blood of patients with gastric cancer was found to be higher than that of healthy controls (69.1 ng/μL vs. 34.8 ng/μL). Patients with cfDNA ≤ 50 ng/μL were found to have an increased overall survival (OS) and progression free survival (PFS) than in patients with cfDNA > 50 ng/μL.","PeriodicalId":38592,"journal":{"name":"Forum of Clinical Oncology","volume":"12 1","pages":"72 - 76"},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47257990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}